Johnson & Johnson reported first-quarter 2026 financial results that exceeded Wall Street’s expectations, driven by its innovative medicine division which... Read more
J&J tops estimates as oncology and new immunology drugs offset Stelara’s decline
15/04/2026
Published by vivi
